Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: dlc who wrote (7532)	10/25/1998 9:41:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Everything is a waste of time! I agree with you almost totally, but there is one "use". The data provides some insight into final accrual rate potential for the trial. The data also indicates that management understanding that it could add a significant number of additional accruals probably did not want an early halt, as this, even if Neuprex works, would have meant a lower P level. Accruals stood at 268 about a week ago. I believe some at XOMA think they will reach a bit over 300 by the trials end. The data IMO indicate that lab confirmed cases will reach 80 per week at the end of the year. How many of these will end up in the trials is of course another thing. The data makes me think it would not be impossible for the total in the trials to reach 350. This is an opinion only but it is one I would not have been able to reach without the data. You are right about the need to determine the effectiveness of BPI but this is data we are not going to get. From the site I learned that GPs in the U.K. all carry a specific antibiotic for use on meningococcal infection. If the trials are a success and BPI works does this information have any implications for XOMA and how BPI might be used? BTW like it or not, useful or not, I am going to continue to provide the URL for the 5 week moving averages, especially. I like the colors and the patterns formed by the data. <g>